Just back from the GRC on Synthetic Lethality in Oncology: great science, deep discussion, great venue and flawless organisation. Thanks to @mgarnett.bsky.social, Benjamin Schwartz & @vazquezf.bsky.social for leading a fantastic meeting at the frontier of cancer research #SyntheticLethality #GRC
July 25, 2025 at 3:36 PM
Just back from the GRC on Synthetic Lethality in Oncology: great science, deep discussion, great venue and flawless organisation. Thanks to @mgarnett.bsky.social, Benjamin Schwartz & @vazquezf.bsky.social for leading a fantastic meeting at the frontier of cancer research #SyntheticLethality #GRC
Enjoying the Gordon Conference on Synthetic Lethality in Oncology with @francescoiorio.bsky.social and @maxbillmann.bsky.social 😊 #bioinformatics #gordonConference #syntheticLethality
July 24, 2025 at 5:58 PM
Enjoying the Gordon Conference on Synthetic Lethality in Oncology with @francescoiorio.bsky.social and @maxbillmann.bsky.social 😊 #bioinformatics #gordonConference #syntheticLethality
Just landed in Chicago for #AACR25 — Millennium Park in bloom! Excited for team talks on WRN inhibitors in MSI cancers, with first-in-human data discussed by @mgarnett.bsky.social at the Clinical Trials Plenary. I’ll present new data on WRNi-driven evolution — Poster #420! #MSI #SyntheticLethality
April 25, 2025 at 4:02 PM
Just landed in Chicago for #AACR25 — Millennium Park in bloom! Excited for team talks on WRN inhibitors in MSI cancers, with first-in-human data discussed by @mgarnett.bsky.social at the Clinical Trials Plenary. I’ll present new data on WRNi-driven evolution — Poster #420! #MSI #SyntheticLethality
A new postdoc position in our group will open early next year — looking for candidates with a proven track record & relevant experience.
If #CRISPRscreens, #syntheticlethality, #smallmolecules & #celldeath excite you, let’s talk! DMs welcome.
pls share 🙏
If #CRISPRscreens, #syntheticlethality, #smallmolecules & #celldeath excite you, let’s talk! DMs welcome.
pls share 🙏
August 4, 2025 at 2:39 PM
A new postdoc position in our group will open early next year — looking for candidates with a proven track record & relevant experience.
If #CRISPRscreens, #syntheticlethality, #smallmolecules & #celldeath excite you, let’s talk! DMs welcome.
pls share 🙏
If #CRISPRscreens, #syntheticlethality, #smallmolecules & #celldeath excite you, let’s talk! DMs welcome.
pls share 🙏
(1/3) Excited to share our latest work using
@depmap.org to uncover a new synthetic lethality in two distinct patient populations!
We found that SKI complex inactivation through two independent genomic alterations creates a dependency on PELO
#CancerResearch #SyntheticLethality #Genomics #DepMap
@depmap.org to uncover a new synthetic lethality in two distinct patient populations!
We found that SKI complex inactivation through two independent genomic alterations creates a dependency on PELO
#CancerResearch #SyntheticLethality #Genomics #DepMap
SKI complex loss renders 9p21.3-deleted or MSI-H cancers dependent on PELO - Nature
Analysis of large-scale CRISPR screening data, combined with experiments in patient-derived tumour organoid models, identifies PELO as a potential therapeutic target in chromosomal 9p21.3-deleted canc...
nature.com
February 6, 2025 at 1:07 PM
(1/3) Excited to share our latest work using
@depmap.org to uncover a new synthetic lethality in two distinct patient populations!
We found that SKI complex inactivation through two independent genomic alterations creates a dependency on PELO
#CancerResearch #SyntheticLethality #Genomics #DepMap
@depmap.org to uncover a new synthetic lethality in two distinct patient populations!
We found that SKI complex inactivation through two independent genomic alterations creates a dependency on PELO
#CancerResearch #SyntheticLethality #Genomics #DepMap
The research will be performed in collaboration with the group of Sylvie Noordermeer at the Leiden University Medical Center.
Congratulations to all involved! (2/2)
#Cancer #DrugDiscovery #SyntheticLethality
CC: @leidenscience.bsky.social
Congratulations to all involved! (2/2)
#Cancer #DrugDiscovery #SyntheticLethality
CC: @leidenscience.bsky.social
August 12, 2026 at 1:09 PM
The research will be performed in collaboration with the group of Sylvie Noordermeer at the Leiden University Medical Center.
Congratulations to all involved! (2/2)
#Cancer #DrugDiscovery #SyntheticLethality
CC: @leidenscience.bsky.social
Congratulations to all involved! (2/2)
#Cancer #DrugDiscovery #SyntheticLethality
CC: @leidenscience.bsky.social
🧬 New preprint out!
Dilara Akhoundova and team identify AURKA as a synthetic lethal vulnerability in FANCA-deficient cancers using complementary CRISPR and drug screens.
🔗 doi.org/10.64898/202...
#PrecisionOncology #SyntheticLethality #FANCA #AURKA #CancerGenomics
Dilara Akhoundova and team identify AURKA as a synthetic lethal vulnerability in FANCA-deficient cancers using complementary CRISPR and drug screens.
🔗 doi.org/10.64898/202...
#PrecisionOncology #SyntheticLethality #FANCA #AURKA #CancerGenomics
February 7, 2026 at 9:33 PM
🧬 New preprint out!
Dilara Akhoundova and team identify AURKA as a synthetic lethal vulnerability in FANCA-deficient cancers using complementary CRISPR and drug screens.
🔗 doi.org/10.64898/202...
#PrecisionOncology #SyntheticLethality #FANCA #AURKA #CancerGenomics
Dilara Akhoundova and team identify AURKA as a synthetic lethal vulnerability in FANCA-deficient cancers using complementary CRISPR and drug screens.
🔗 doi.org/10.64898/202...
#PrecisionOncology #SyntheticLethality #FANCA #AURKA #CancerGenomics
Discover #syntheticLethality: using CRISPR-Cas9 tech to identify new therapeutic targets in cancer, tackling undruggable pathways. Breakthroughs in treatment loom. #cancer #innovation PMID:39627502, Nat Rev Clin Oncol 2024 doi.org/10.1038/s415...
Synthetic lethal strategies for the development of cancer therapeutics - Nature Reviews Clinical Oncology
The experience with PARP inhibitors provides evidence of the clinical utility of synthetic lethality, whereby the simultaneous presence of two specific alterations is required for antitumour activity....
doi.org
December 27, 2024 at 1:18 AM
Discover #syntheticLethality: using CRISPR-Cas9 tech to identify new therapeutic targets in cancer, tackling undruggable pathways. Breakthroughs in treatment loom. #cancer #innovation PMID:39627502, Nat Rev Clin Oncol 2024 doi.org/10.1038/s415...
#SyntheticLethality offers a new path in #ColorectalCancer.
In APC‑deficient cells, ALDH2 inhibition with disulfiram elevates ROS, activates ASK1/JNK signaling, and drives apoptosis, revealing a therapeutic strategy against APC mutations.
#GenesAndDiseases: doi.org/10.1016/j.ge...
In APC‑deficient cells, ALDH2 inhibition with disulfiram elevates ROS, activates ASK1/JNK signaling, and drives apoptosis, revealing a therapeutic strategy against APC mutations.
#GenesAndDiseases: doi.org/10.1016/j.ge...
August 23, 2026 at 4:28 AM
#SyntheticLethality offers a new path in #ColorectalCancer.
In APC‑deficient cells, ALDH2 inhibition with disulfiram elevates ROS, activates ASK1/JNK signaling, and drives apoptosis, revealing a therapeutic strategy against APC mutations.
#GenesAndDiseases: doi.org/10.1016/j.ge...
In APC‑deficient cells, ALDH2 inhibition with disulfiram elevates ROS, activates ASK1/JNK signaling, and drives apoptosis, revealing a therapeutic strategy against APC mutations.
#GenesAndDiseases: doi.org/10.1016/j.ge...
#SyntheticLethality is not only about new targets — it’s about treating the right patients in the right way.
With Hyper-C, Delta4 connects multi-omics data to prioritize synthetic lethal interactions and enable smarter patient selection and trial design. Read more:
🔗 delta4.ai/synthetic-lethality
With Hyper-C, Delta4 connects multi-omics data to prioritize synthetic lethal interactions and enable smarter patient selection and trial design. Read more:
🔗 delta4.ai/synthetic-lethality
July 16, 2026 at 11:20 AM
#SyntheticLethality is not only about new targets — it’s about treating the right patients in the right way.
With Hyper-C, Delta4 connects multi-omics data to prioritize synthetic lethal interactions and enable smarter patient selection and trial design. Read more:
🔗 delta4.ai/synthetic-lethality
With Hyper-C, Delta4 connects multi-omics data to prioritize synthetic lethal interactions and enable smarter patient selection and trial design. Read more:
🔗 delta4.ai/synthetic-lethality
Of the Blackman’s in science, this one has the best hair and best headshot. #SABCS2017 #syntheticlethality
December 1, 2024 at 11:27 PM
Of the Blackman’s in science, this one has the best hair and best headshot. #SABCS2017 #syntheticlethality
#pharmalicensingdeals #pharmaceuticalassets #VirBiotech #Vir #HarbourBioMed #UnnaturalProducts #Genhouse #CSL #Astellas #SolsticeOncology #antiCTLA4antibody #Novartis #UnnaturalProducts #macrocyclicpeptidedrugs #GileadSciences #syntheticlethality #GenhouseBio #Arcellx #EliLilly
zurl.co/HOdjt
zurl.co/HOdjt
Astellas bets on Vir cancer drug, and other licensing deals
Our latest round-up of pharma licensing deals features assets from Vir Biotech, Harbour BioMed, Unnatural Products, Genhouse, and CSL.
zurl.co
February 25, 2026 at 12:05 PM
Synthetic Lethality is redefining cancer treatment across the globe. With a CAGR of 14.6%, the global market is expanding fast, from USD 1.3B in 2024 to USD 3.87B by 2032.
👉 Access Full Report: www.credenceresearch.com/report/synth...
#AIinHealthcare #DrugDiscovery #SyntheticLethality
👉 Access Full Report: www.credenceresearch.com/report/synth...
#AIinHealthcare #DrugDiscovery #SyntheticLethality
April 29, 2025 at 6:34 AM
Synthetic Lethality is redefining cancer treatment across the globe. With a CAGR of 14.6%, the global market is expanding fast, from USD 1.3B in 2024 to USD 3.87B by 2032.
👉 Access Full Report: www.credenceresearch.com/report/synth...
#AIinHealthcare #DrugDiscovery #SyntheticLethality
👉 Access Full Report: www.credenceresearch.com/report/synth...
#AIinHealthcare #DrugDiscovery #SyntheticLethality